Zoetis (NYSE:ZTS) Issues FY 2020 Pre-Market Earnings Guidance

Zoetis (NYSE:ZTS) updated its FY 2020
Pre-Market earnings guidance on Thursday. The company provided earnings per share guidance of 3.90-4.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.01. The company issued revenue guidance of $6.65-6.8 billion, compared to the consensus revenue estimate of $6.7 billion.Zoetis also updated its FY20 guidance to $3.90-4.00 EPS.

Several analysts have commented on the stock. Bank of America restated a hold rating and set a $145.00 price objective on shares of Zoetis in a research note on Wednesday. Cfra upgraded shares of Zoetis from a buy rating to a strong-buy rating and lifted their price objective for the company from $147.00 to $160.00 in a research note on Thursday. Zacks Investment Research upgraded shares of Zoetis from a hold rating to a buy rating and set a $142.00 price objective for the company in a research note on Thursday, December 26th. SunTrust Banks restated a hold rating and set a $145.00 price objective on shares of Zoetis in a research note on Friday. Finally, Morgan Stanley lifted their price objective on shares of Zoetis from $136.00 to $148.00 and gave the company an equal weight rating in a research note on Friday. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $135.53.

NYSE ZTS traded down $0.77 on Friday, hitting $144.17. 1,809,841 shares of the company’s stock traded hands, compared to its average volume of 2,018,624. The company has a current ratio of 4.39, a quick ratio of 3.02 and a debt-to-equity ratio of 2.47. The firm’s 50-day moving average price is $136.94 and its two-hundred day moving average price is $127.01. Zoetis has a 1-year low of $91.21 and a 1-year high of $146.26. The firm has a market capitalization of $67.90 billion, a PE ratio of 47.58, a P/E/G ratio of 3.10 and a beta of 0.81.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.04. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The firm had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period in the previous year, the business posted $0.79 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. On average, research analysts anticipate that Zoetis will post 3.6 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, April 17th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend is Thursday, April 16th. Zoetis’s dividend payout ratio is currently 25.56%.

In related news, EVP Andrew Fenton sold 12,705 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $120.30, for a total value of $1,528,411.50. Following the completion of the transaction, the executive vice president now directly owns 21,530 shares in the company, valued at approximately $2,590,059. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Heidi C. Chen sold 15,329 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $139.81, for a total transaction of $2,143,147.49. Following the completion of the transaction, the executive vice president now owns 26,792 shares of the company’s stock, valued at $3,745,789.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 125,001 shares of company stock valued at $15,342,770. Company insiders own 0.29% of the company’s stock.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: What Does a Sell-Side Analyst Rating Mean?

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.